`Filed: January 25, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`___________________
`
`
`
`COALITION FOR AFFORDABLE DRUGS VI LLC
`
`PETITIONER
`
`V.
`
`CELEGENE CORPORATION
`
`PATENT OWNER
`
`
`
`___________________
`
`Case IPR2015-01103
`Patent 6,315,720
`___________________
`
`
`
`PETITIONER’S MOTION TO SUBMIT SUPPLEMENTAL
`INFORMATION PURUSUANT TO 37 C.F.R. § 42.123(a)
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.123(a), Petitioner Coalition For Affordable
`
`Case IPR2015-01103
`Patent 6,315,720
`
`
`
`Drugs VI LLC (“CFAD”) hereby moves to submit supplemental information in
`
`accordance with the Order dated December 9, 2015 (Paper 34) in Case IPR2015-
`
`01103. The Patent Owner indicated that it opposes this motion.
`
`I. The Present Motion Complies with the Rules
`
`1. The present motion complies with the requirements of 37 CFR §
`
`42.123(a)(1), as set forth below:
`
`2. 37 CFR § 42.123(a)(1): The Board instituted the inter partes review of U.S.
`
`Patent 6,315,720 in a Decision dated October 27, 2015. (Paper 22.) Petitioner’s
`
`request for authorization was timely made within one month of institution. (See e-
`
`mail communication to the Board and Patent Owner on November 27, 2015.)
`
`3. 37 CFR § 42.123(a)(2): In this proceeding, trial has not been instituted for
`
`Claims 1–32 based on FDA Meeting Transcripts (Exs. 1012, 1013) or CDC
`
`minutes (Ex. 1014). Specifically, Petitioner relies on these references to explain the
`
`state of the relevant art at the time of the invention. (Paper 1 at 13–14.)
`
`4. Patent Owner objected to the admissibility of evidence submitted during the
`
`preliminary proceedings— FDA Meeting Transcripts (Exs. 1012, 1013) and CDC
`
`minutes (Ex. 1014). (Paper 24.)
`
`
`
`1
`
`
`
`5. Pursuant to 37 C.F.R. § 42.64(b)(2), Petitioner timely responded to Patent
`
`Case IPR2015-01103
`Patent 6,315,720
`
`
`
`Owner’s objections to evidence submitted during the preliminary proceeding with
`
`service of the following supplemental evidence:
`
`Evidence
`
`Exhibit 1012 &
`1013 (FDA
`Meeting
`Transcript
`
`Exhibit 1014
`(CDC Minutes)
`
`
`
`
`
`Supplemental Evidence Submitted in
`Response
`
`Patent
`Owner’s
`Objection
`FRE 901, 802 Exhibit 1074 - Oct. 12, 2011 Information
`Disclosure Statement, Application No.
`12/966,240 (resulting in U.S. Patent No.
`8,204,763)
`
`FRE 901, 802 Exhibit 1075 - Sep. 19, 2011 Information
`Disclosure Statement, Application No.
`12/966,261 (resulting in U.S. Patent No.
`8,315,886)
`
`Exhibit 1076 - Federal Register Volume 62,
`Number 53 (March 19, 1997)
`
`II. The Supplemental Information
`
`6. As mentioned above, the present IPR refers to FDA Meeting Transcripts and
`
`CDC minutes, and the supplemental information regarding these references having
`
`been served on Patent Owner, Petitioner seeks to file the above supplemental
`
`evidence as supplemental information.
`
`III. Conclusion
`
`The supplemental information Petitioner seeks to submit does not change the
`
`grounds of unpatentability on which the inter partes review has been instituted, nor
`
`
`
`2
`
`
`
`
`does it change the evidence initially presented in the Petition to support such
`
`Case IPR2015-01103
`Patent 6,315,720
`
`grounds of unpatentability. Instead, the supplemental information merely
`
`constitutes additional information that confirms public accessibility/availability of
`
`FDA Meeting Transcripts (Exs. 1012, 1013) and CDC minutes (Ex. 1014), and this
`
`supplemental information was neither withheld intentionally nor would it limit or
`
`frustrate the Board’s ability to complete this proceeding in a timely manner.
`
`For the foregoing reasons, Petitioner requests the Board to accept this
`
`motion.
`
`January 25, 2016
`
`
`
`Dr. Parvathi Kota (Reg. No. 65,122)
`Paul J. Skiermont (pro hac vice)
`SKIERMONT DERBY LLP
`2200 Ross Ave. Ste. 4800W
`Dallas, Texas 75201
`P: 214-978-6600/F: 214-978-6621
`Back-Up Counsel for Petitioner
`
`
`
`3
`
`Respectfully submitted,
`
`
`
`
`
`Sarah E. Spires (Reg. No. 61,501)
`SKIERMONT DERBY LLP
`2200 Ross Ave. Ste. 4800W
`Dallas, Texas 75201
`P: 214-978-6600/F: 214-978-6601
`Lead Counsel for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2015-01103
`Patent 6,315,720
`
`I hereby certify that on January 25, 2016, a copy of this Motion, including
`
`all exhibits, was served via email upon the following:
`
`Francis Cerrito
`nickcerrito@quinnemanuel.com
`
`Eric C. Stops
`ericstops@quinnemanuel.com
`
`Frank C. Calvosa
`frankcalvosa@quinnemanuel.com
`
`Anthony Insogna
`aminsogna@jonesday.com
`
`J. Patrick Elsevier
`jpelsevier@jonesday.com
`
`Gasper J. LaRosa
`gjlarosa@jonesday.com
`
`
`
`Date: January 25, 2016
`
`
`
`
`
`
`
`/Sarah E. Spires/
`
`
`
`
`
`
`
`
`
`